BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Protagonist Therapeutics readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Protagonist Therapeutics's drugs 
 run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06807424-19@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20270210
DTEND;VALUE=DATE:20270211
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT06807424)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) 
 in Biologic-experienced and Biologic-naive Participants With Active Psoria
 tic Arthritis\nEstimated primary completion: 10 February 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06807424
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07648030-10912@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:rusfertide: Phase 2 readout est. (NCT07648030)
DESCRIPTION:rusfertide\, phase 2\, Polycythemia Vera.\nStudy: A Study of Ru
 sfertide in Japanese Adults With Polycythemia Vera\nEstimated primary comp
 letion: 28 October 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/rusfertide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07648030
URL:https://assetmemo.bio/drug/rusfertide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196748-19@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280114
DTEND;VALUE=DATE:20280115
SUMMARY:Icotyde (icotrokinra): Phase 3 readout est. (NCT07196748)
DESCRIPTION:Icotyde (icotrokinra)\, phase 3\, Ulcerative Colitis.\nStudy: A
  Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With
  Moderately to Severely Active Ulcerative Colitis\nEstimated primary compl
 etion: 14 January 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/icotrokinra#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07196748
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765602-10912@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:rusfertide: Phase 2 readout est. (NCT07765602)
DESCRIPTION:rusfertide\, phase 2\, Polycythemia Vera.\nStudy: A Study of Ru
 sfertide in Adults With Polycythemia Vera in China\nEstimated primary comp
 letion: 1 July 2028. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 rusfertide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07765602
URL:https://assetmemo.bio/drug/rusfertide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07196722-19@assetmemo.bio
DTSTAMP:20261121T005721Z
DTSTART;VALUE=DATE:20280919
DTEND;VALUE=DATE:20280920
SUMMARY:Icotyde (icotrokinra): Phase 2/3 readout est. (NCT07196722)
DESCRIPTION:Icotyde (icotrokinra)\, phase 2/3\, Crohn's Disease.\nStudy: A 
 Study of Icotrokinra in Participants With Moderately to Severely Active Cr
 ohn's Disease\nEstimated primary completion: 19 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/icotrokinra#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07196722
URL:https://assetmemo.bio/drug/icotrokinra#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
